MEREO BIOPHARMA GROUP PLC's ticker is MREO and the CUSIP is 589492107. A total of 49 filers reported holding MEREO BIOPHARMA GROUP PLC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $574,676 | +24.0% | 445,485 | +26.9% | 0.02% | +17.6% |
| Q2 2023 | $463,300 | +7.9% | 350,985 | -42.2% | 0.02% | 0.0% |
| Q1 2023 | $429,442 | +84.4% | 607,500 | +95.7% | 0.02% | +54.5% |
| Q4 2022 | $232,875 | -12.8% | 310,500 | 0.0% | 0.01% | -15.4% |
| Q3 2022 | $267,000 | +13.6% | 310,500 | +47.9% | 0.01% | +18.2% |
| Q2 2022 | $235,000 | -3.3% | 210,000 | -3.2% | 0.01% | 0.0% |
| Q1 2022 | $243,000 | +125.0% | 217,051 | +221.6% | 0.01% | +83.3% |
| Q4 2021 | $108,000 | -81.5% | 67,501 | -72.0% | 0.01% | -79.3% |
| Q3 2021 | $584,000 | -70.6% | 241,413 | -61.5% | 0.03% | -62.3% |
| Q2 2021 | $1,986,000 | +836.8% | 626,421 | +898.0% | 0.08% | +1000.0% |
| Q1 2021 | $212,000 | -87.1% | 62,767 | -86.4% | 0.01% | -91.7% |
| Q4 2020 | $1,647,000 | +41.7% | 460,051 | +3.7% | 0.08% | +6.3% |
| Q3 2020 | $1,162,000 | – | 443,517 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 1,854,278 | $6,638,000 | 3.61% |
| Asymmetry Capital Management, L.P. | 739,812 | $2,649,000 | 1.21% |
| Affinity Asset Advisors, LLC | 625,000 | $2,238,000 | 1.19% |
| Tri Locum Partners LP | 728,710 | $2,609,000 | 0.95% |
| Boxer Capital, LLC | 6,226,673 | $22,291,000 | 0.72% |
| DAFNA Capital Management LLC | 668,148 | $2,392,000 | 0.71% |
| Vivo Capital, LLC | 4,220,938 | $15,111,000 | 0.67% |
| Delphi Management Partners VIII, L.L.C. | 256,734 | $919,000 | 0.60% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 280,000 | $1,002,000 | 0.58% |
| Rubric Capital Management LP | 1,853,417 | $6,635,000 | 0.49% |